-
-
12.发明公开
公开(公告)号：EP3845555A1
公开(公告)日：2021-07-07
申请号：EP20181803.6
申请日：2020-06-23
申请人： Algaeprona Inc.
发明人： Shin, Bok Kyu , Kwon, Byeo Ri , Kim, Seul Ki
摘要： The present invention provides a vector for producing and expressing human growth factors and microalgae transformed with the vector.
-
公开(公告)号：EP3710043A1
公开(公告)日：2020-09-23
申请号：EP18803673.5
申请日：2018-11-16
-
-
公开(公告)号：EP3636663A1
公开(公告)日：2020-04-15
申请号：EP18791988.1
申请日：2018-04-11
发明人： WANG, Junfeng , ZHAO, Hongxin , ZHU, Lei
摘要： The present disclosure relates to a human FGF21 mutant, a preparation method and a use thereof, and specifically relates to a human fibroblast growth factor 21 (FGF21) mutant, a gene encoding the same, and a method for preparing the mutant and a method of using the mutant for treating type 2 diabetes, obesity, dyslipidemia, or metabolic disorders.
-
公开(公告)号：EP3227320B1
公开(公告)日：2019-07-03
申请号：EP15865723.9
申请日：2015-12-02
发明人： BLABER, Michael , XIA, Xue
-
公开(公告)号：EP3380508A1
公开(公告)日：2018-10-03
申请号：EP16781318.7
申请日：2016-10-03
发明人： DVORAK, Petr , KREJCI, Pavel , BALEK, Lukas , EISELLEOVA, Livia , KONECNA, Zaneta , DVORAK, Pavel , BEDNAR, David , BREZOVSKY, Jan , SEBESTOVA, Eva , CHALOUPKOVA, Radka , STEPANKOVA, Veronika , VANACEK, Pavel , PROKOP, Zbynek , DAMBORSKY, Jiri , BOSAKOVA, Michaela
IPC分类号： C07K14/50
摘要： The invention provides an isolated thermostable polypeptide possessing FGF2 activity and having at least 85% sequence identity to SEQ ID NO: 2 (FGF2 wt) or a functional fragment thereof, and comprising at least one amino acid substitution R31L and the use thereof in the cell biology research, regenerative medicine and related medical applications or cosmetics. Further it discloses a culture medium comprising subjected FGF2 suitable for culturing a human pluripotent stem cells involving both human embryonic stem cells and induced pluripotent stem cells.
-
18.发明公开
公开(公告)号：EP3368059A1
公开(公告)日：2018-09-05
申请号：EP16860818.0
申请日：2016-10-27
CPC分类号： A61K38/1825 , A61K31/00 , A61K31/573 , A61K45/06 , A61P3/10 , C07K14/50 , C07K14/501 , C07K2319/70 , A61K2300/00
摘要： Methods of using FGF1 analogs, such as FGF1 mutant proteins having an N-terminal deletion, point mutation(s), or combinations thereof, to reduce blood glucose levels in subjects with steroid-induced diabetes, hypercortisolemia, or diabetes due to treatment with an antipsychotic agent, are provided. Such mutant FGF1 proteins can be part of a chimeric protein that includes a β-Klotho-binding protein, an FGFR1-binding protein, a β-Klotho-binding protein and a FGFR1-binding protein, a C-terminal region from FGF19 or FGF21.
-
19.发明公开
公开(公告)号：EP3155005A4
公开(公告)日：2018-07-11
申请号：EP15810176
申请日：2015-06-15
CPC分类号： A61K38/28 , A61K31/155 , A61K31/165 , A61K31/519 , A61K31/52 , A61K31/573 , A61K31/575 , A61K31/64 , A61K38/13 , A61K38/1825 , A61K38/208 , A61K38/26 , A61K45/06 , C07K14/50 , C07K2319/00 , A61K2300/00
摘要： Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
-
公开(公告)号：EP3321276A3
公开(公告)日：2018-06-20
申请号：EP17201957.2
申请日：2012-09-26
申请人： Novartis AG
发明人： BOETTCHER, Brian R. , CAPLAN, Shari L. , DANIELS, Douglas S. , HAMAMATSU, Norio , LICHT, Stuart , WELDON, Stephen Craig
IPC分类号： C07K14/50
CPC分类号： A61K38/1825 , A61K38/00 , A61K45/06 , C07K14/50 , C07K2319/30
摘要： The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
-
-
-
-
-
-
-
-
-
搜索结果
499 条记录 (耗时 0.019 秒)
